BCR/ABL 210 kD fusion protein (259-269)

BCR/ABL 210 kD fusion protein (259-269) is a synthetic peptide fragment corresponding to amino acids 259 to 269 of the BCR/ABL fusion region, a hallmark of the Philadelphia chromosome translocation found in chronic myeloid leukemia (CML) and certain acute lymphoblastic leukemias (ALL). As a well-characterized peptide derived from the junctional region of the BCR and ABL genes, it serves as a critical molecular tool for studying the biochemical and cellular consequences of oncogenic fusion proteins. Its unique sequence, absent from native BCR or ABL proteins, allows for highly specific interrogation of fusion-driven signaling pathways and immune recognition events in a variety of experimental systems.

Epitope mapping: The peptide is frequently employed in epitope mapping studies to identify and characterize antibody binding sites specific to the BCR/ABL fusion region. By presenting the precise amino acid sequence formed at the fusion junction, it enables researchers to generate and validate monoclonal or polyclonal antibodies with high specificity for the oncogenic protein, supporting the development of immunodetection assays and facilitating the study of immune surveillance mechanisms against leukemia-associated antigens.

Immunoassay development: In the context of diagnostic and research immunoassays, the BCR/ABL 210 kD fusion protein (259-269) peptide serves as a standardized antigen for the calibration and validation of enzyme-linked immunosorbent assays (ELISA), western blotting, and other antibody-based detection platforms. Its defined sequence and synthetic origin ensure reproducibility and specificity, making it a valuable reagent for monitoring minimal residual disease, quantifying fusion protein expression, or benchmarking assay performance in translational research settings.

T cell response analysis: The peptide sequence is utilized in studies examining cellular immune responses, particularly those involving cytotoxic T lymphocytes (CTLs) that recognize leukemia-specific epitopes. In vitro stimulation of patient-derived or experimental T cells with the fusion peptide enables assessment of antigen-specific proliferation, cytokine production, or cytolytic activity, providing insights into anti-leukemic immunity and informing the design of peptide-based immunotherapies or vaccine candidates.

Signal transduction research: As a model substrate, the BCR/ABL fusion region peptide is instrumental in dissecting the molecular mechanisms of aberrant kinase signaling associated with the Philadelphia chromosome. It can be used in kinase assays or structural studies to investigate substrate recognition, phosphorylation patterns, and downstream signaling events triggered by the oncogenic tyrosine kinase activity of the fusion protein, thereby advancing our understanding of leukemogenesis and drug resistance mechanisms.

Peptide-based assay controls: The synthetic peptide serves as a reliable positive or negative control in a variety of peptide-based analytical techniques. Its use ensures the specificity and sensitivity of experimental workflows, including mass spectrometry, high-performance liquid chromatography (HPLC), and peptide array screening. By providing a well-defined and disease-relevant standard, the peptide supports rigorous quality control and reproducibility in research focused on fusion protein detection, quantitation, and functional analysis.

1. An Open-label, Single-center, Safety and Efficacy Study of Eyelash Polygrowth Factor Serum

2. Immune responses to peptides containing homocitrulline or citrulline in the DR4-transgenic mouse model of rheumatoid arthritis

3. Adipose tissue is a key organ for the beneficial effects of GLP-2 metabolic function

4. Effect of Probiotic Lactobacillus plantarum on Streptococcus mutans and Candida albicans Clinical Isolates from Children with Early Childhood Caries

5. Glucagonlike peptide 2 analogue teduglutide: stimulation of proliferation but reduction of differentiation in human Caco-2 intestinal epithelial cells